| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Choerospondin targets the MAPK/NF-κB signaling pathway, inhibiting inflammatory responses. It acts as a potential α-glucosidase inhibitor. The compound modulates cholesterol efflux in ox-LDL-loaded foam cells. It also enhances resistance to oxidative stress. Its anti-atherosclerotic activity is linked to reducing NO production in LPS-induced macrophages.
|
|---|---|
| ln Vitro |
In vitro, Choerospondin exhibits significant anti-inflammatory activity by attenuating MAPK phosphorylation and NF-κB activation. It demonstrates antiproliferative effects against various cancer cell lines. As an α-glucosidase inhibitor, it may help regulate glucose metabolism. The compound also shows antioxidant activity by enhancing resistance to oxidative stress. It modulates cholesterol efflux in foam cells.
|
| ln Vivo |
In vivo, Choerospondin has demonstrated hepatoprotective effects against polystyrene microplastic-induced injury. It exhibits anti-inflammatory and anti-atherosclerotic activities. The compound's potential for anti-obesity effects has also been noted. Studies suggest it may contribute to regulating oxidative stress, modulating immune pathways, and protecting against chronic disease progression.
|
| Enzyme Assay |
In vitro enzyme assays for Choerospondin typically measure its inhibition of α-glucosidase activity. The enzyme is incubated with a substrate (e.g., p-nitrophenyl-α-D-glucopyranoside) in the presence of varying concentrations of the compound. The release of p-nitrophenol is measured spectrophotometrically. IC50 values are calculated from inhibition curves.
|
| Cell Assay |
Cell-based assays for Choerospondin are performed using LPS-induced macrophages to study its anti-inflammatory effects. Cells are treated with the compound, and the production of NO and inflammatory cytokines is measured. Foam cell models using ox-LDL-loaded macrophages are used to assess its effects on cholesterol efflux. MAPK/NF-κB pathway modulation is evaluated by Western blotting.
|
| Animal Protocol |
In vivo animal studies with Choerospondin are conducted in models of oxidative stress and inflammation. For example, hepatoprotective effects can be assessed in models of polystyrene microplastic-induced liver injury. The compound is typically administered orally, and endpoints include liver enzyme levels, histopathology, and markers of oxidative stress and inflammation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Choerospondin are limited. Its molecular weight is 434.39 g/mol. The compound is a glycosylated flavanone with enhanced DMSO solubility (≥100 mg/mL) compared to its aglycone naringenin. For research use, it is typically dissolved in DMSO for in vitro studies. Its oral bioavailability and metabolic stability have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for Choerospondin are limited. No significant adverse effects have been reported in the studies described. The compound is a natural product with a generally favorable safety profile. It should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
According to reports, 4H-1-benzopyran-4-one, 2-(4-(β-D-pyranoglucopyranoyl)phenyl)-2,3-dihydro-5,7-dihydroxy-,(2S)- exists in Juniperus chinensis and Juniperus dwarfusa varieties, and relevant data are available.
Choerospondin is a natural flavonoid glycoside with diverse pharmacological activities, including anti-inflammatory, antioxidant, anti-atherosclerotic, and hepatoprotective effects. It is a potential α-glucosidase inhibitor and a modulator of the MAPK/NF-κB pathway. The compound is being investigated for its therapeutic potential in metabolic and inflammatory diseases. It is not approved for clinical use and is intended for laboratory research only. |
| Molecular Formula |
C21H22O10
|
|---|---|
| Molecular Weight |
434.3934
|
| Exact Mass |
434.121
|
| CAS # |
81202-36-0
|
| PubChem CID |
157745
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
623
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
KSDSYIXRWHRPMN-SFTVRKLSSA-N
|
| InChi Code |
InChI=1S/C21H22O10/c22-8-16-18(26)19(27)20(28)21(31-16)29-11-3-1-9(2-4-11)14-7-13(25)17-12(24)5-10(23)6-15(17)30-14/h1-6,14,16,18-24,26-28H,7-8H2/t14-,16+,18+,19-,20+,21+/m0/s1
|
| Chemical Name |
(2S)-5,7-dihydroxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2,3-dihydrochromen-4-one
|
| Synonyms |
Choerospondin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~230.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3021 mL | 11.5104 mL | 23.0208 mL | |
| 5 mM | 0.4604 mL | 2.3021 mL | 4.6042 mL | |
| 10 mM | 0.2302 mL | 1.1510 mL | 2.3021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
